

Datasheet for MB-030-0250

1X RIPA Lysis Buffer

Overview

Description:	1X RIPA Lysis Buffer 5-PACK (5 x 50 ml) - MB-030-0250
Item No.:	MB-030-0250
Size:	5 x 50 mL
Applications:	ChIP, IP, WB, Other

Product Details

Background:

RIPA (Radio-Immunoprecipitation Assay) Lysis Buffer enables rapid, efficient cell lysis and solubilization of proteins from both adherent and suspension cultured mammalian cells. It has long been a widely used lysis and wash buffer for small-scale affinity pull-down applications, such as immunoprecipitation, since most antibodies and protein antigens are not adversely affected by the components of this buffer. In addition, RIPA Lysis Buffer minimizes non-specific protein-binding interactions to keep background low, while allowing most specific interactions to occur, enabling studies of relevant protein-protein interactions. The following RIPA Lysis Buffer components have the following effects: Tris-HCl is a buffering agent prevents protein denaturation, NaCl is a salt that prevents non-specific protein aggregation, IGEPAL® CA-630 is a non-ionic detergent to extract proteins; Na-deoxycholate and SDS are ionic detergents to extract proteins; and sodium azide is a bacteriostatic agent added to retard bacterial growth. RIPA Lysis Buffer is supplied as a ready-to-use solution that requires no preparation. We suggest that the user add protease and phosphatase inhibitors not included with this product prior to use.

Synonyms:	1X RIPA Lysis Buffer, 1X RIPA (Radio-Immunoprecipitation Assay) Lysis Buffer
------------------	--

Target Details

Purity/Specificity:	This product was aseptically filtered through a Millipore 0.22 micron filter into clean, pre-sterilized containers. The product was tested on trypticase soy agar for 24 hours, 48 hours and 72 hours and was found to be negative for bacteria.
----------------------------	--

Relevant Links:	MB-030 SDS RIPA Lysis Buffer Procedure Protocol
------------------------	---

Application Details

Tested Applications:	ChIP, IP, WB
Suggested Applications:	Other (Based on references)
Application Note:	This product is ready-to-use as a working 1X solution and requires no further dilution. 1X RIPA Lysis Buffer is intended for the extraction of cellular proteins for the efficient lysis of cells and solubilization of protein, while minimizing protein degradation and maintaining protein immunoreactivity and biological activity. We recommend using 1.0 ml of RIPA Lysis Buffer to lyse 0.5 to 5 x 10E7 adherent mammalian cells. This buffer contains ionic detergents and may not be suitable for kinase enzymes, if these enzymes are easily denatured. Do not add phosphatase inhibitors when preparing lysates for phosphatase assays. 1X RIPA lysis buffer consists of 50 mM Tris HCl, 150 mM NaCl, 1.0% (v/v) IGEPAL® CA-630, 0.5% (w/v) Sodium Deoxycholate, 1.0 mM EDTA, 0.1% (w/v) SDS and 0.01% (w/v) sodium azide at a pH of 7.4. This buffer was meticulously prepared using ultra pure reagents dissolved in highly polished pharmaceutical grade deionized water. Protease and phosphatase inhibitors are recommended but not included in product composition. Recommended final concentrations of protease inhibitors: 1.0 mM Phenylmethylsulfonyl fluoride (PMSF) 10 µM Leupeptin 0.1 µM Aprotinin 1.0 µM Pepstatin Recommended final concentrations of phosphatase inhibitors: 1.0 mM Na3VO4 1.0 mM NaF
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.

Formulation

Physical State:	Liquid (sterile filtered)
Concentration:	1 X
Buffer:	See application note.
Preservative:	0.01% (w/v) Sodium Azide
Stabilizer:	None

Shipping & Handling

Shipping Condition:	Ambient
Storage Condition:	Store container at room temperature (18° to 26° C) prior to opening. Protect from light (store in the dark).
Expiration:	Expiration date is six (6) months from date of receipt.

References

- Jeong GH et al. A New Class of Hybrid Anti-inflammatory Agents of Silibinin A Modified Using Gamma Irradiation. *Chem Pharm Bull (Tokyo)*. (2025)
- Bhalla M et al. SIRT2 and ALDH1A1 as critical enzymes for astrocytic GABA production in Alzheimer's disease. *Mol Neurodegener*. (2025)
- Nesbitt NM et al. Small molecule BLVRB redox inhibitor promotes megakaryocytopoiesis and stress thrombopoiesis in vivo. *Nat Commun*. (2025)
- Hyun J et al. Strengthening the cellular function of dermal fibroblasts and dermal papilla cells using nanovesicles extracted from stem cells using blue light-based photobiomodulation technology. *Biomatter Sci*. (2025)
- Song Y et al. Unveiling aging heterogeneities in human dermal fibroblasts via nanosensor chemical cytometry. *Nat Commun*. (2025)
- Kim YH et al. Reduction of Low-Density Lipoprotein Cholesterol by Mesenchymal Stem Cells in a Mouse Model of Exogenous Cushing's Syndrome. *Tissue Eng Regen Med*. (2025)
- Kim YJ, et al. Synergistic Ion-Releasing Nanoparticles as a Therapeutic Platform for Modulating Adult Stem Cell Activity in Wound Healing. *Biomater Res*. (2025)
- Kim JU et al. Gold Nanoturf-Mediated Wireless Photothermal Upregulation of Human Adipose-Derived Stem Cell Spheroids for Synergistic Skin-Wound Closure. *Adv Sci (Weinh)*. (2025)
- Shin HS et al. RNF213 variant and autophagic impairment: A pivotal link to endothelial dysfunction in moyamoya disease. *J Cereb Blood Flow Metab*. (2024)
- Lee H et al. Ionizing radiation-induced modification of nialamide as an anti-inflammatory agent against lipopolysaccharide-induced RAW 264.7 and DH82 cells. *Exp Ther Med*. (2024)
- Park A et al. Serum-Free Media Formulation Using Marine Microalgae Extracts and Growth Factor Cocktails for Madin-Darby Canine Kidney and Vero Cell Cultures. *Int J Mol Sci*. (2024)
- Kim JY et al. Combinatory Nanovesicle with siRNA-Loaded Extracellular Vesicle and IGF-1 for Osteoarthritis Treatments. *Int J Mol Sci*. (2024)
- Li Q et al. Nanomodulator-Mediated Restructuring of Adipose Tissue Immune Microenvironments for Antiobesity Treatment. *ACS Nano*. (2024)
- Gastfriend BD et al. Notch3 directs differentiation of brain mural cells from human pluripotent stem cell-derived neural crest. *Sci Adv*. (2024)
- Jeong GH et al. Inhibitory Effects of New Epicatechin Oligomers on Nitric Oxide Production. *Int J Mol Sci*. (2024)

- Lee YB et al. Enhancing skin regeneration efficacy of human dermal fibroblasts using carboxymethyl cellulose-coated biodegradable polymer. *Tissue Eng Regen Med.* (2024)
- Peltier S et al. In vitro effects of wound-dressings on key wound healing properties of dermal fibroblasts. *Exp Dermatol.* (2024)
- Oh HN et al. Copper pyrithione and zinc pyrithione induce cytotoxicity and neurotoxicity in neuronal/astrocytic co-cultured cells via oxidative stress. *Sci Rep.* (2023)
- Park J et al. CRISPR/Cas9 mediated specific ablation of vegfa in retinal pigment epithelium efficiently regresses choroidal neovascularization. *Sci Rep.* (2023)
- Lee J et al. Production of large, defined genome modifications in rats by targeting rat embryonic stem cells. *Stem Cell Reprots.* (2023)
- Yoon SH et al. Molecular traces of Drosophila hemocytes reveal transcriptomic conservation with vertebrate myeloid cells. *PLoS Genet.* (2023)
- Ahn KS et al. Diagnostic Role of Bile Pigment Components in Biliary Tract Cancer. *Biomol Ther (Seoul).* (2023)
- Kwon H et al. Fibronectin Type III Domain Containing 3B as a Potential Prognostic and Therapeutic Biomarker for Glioblastoma. *Biomedicines.* (2023)
- Park SJ et al. Chronic juvenile stress exacerbates neurobehavioral dysfunction and neuroinflammation following traumatic brain injury in adult mice. *Clin Exp Emerg Med.* (2023)
- Lee SH et al. Lactococcus lactis-fermented spinach juice suppresses LPS-induced expression of adhesion molecules and inflammatory cytokines through the NF- κ B pathway in HUVECs. *Exp Ther Med.* (2022)
- Copello VA et al. The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor. *Oncogene.* (2022)
- Kieran NW et al. MicroRNA-210 regulates the metabolic and inflammatory status of primary human astrocytes. *J Neuroinflammation.* (2022)
- Lee, G et al. Effects of an Exercise Program Combining Aerobic and Resistance Training on Protein Expressions of Neurotrophic Factors in Obese Rats Injected with Beta-Amyloid. *International Journal of Environmental Research and Public Health* (2022)
- Chun H et al. Inhibition of monoamine oxidase B prevents reactive astrogliosis and scar formation in stab wound injury model. *Glia.* (2022)
- Kyeong M et al. Endogenous BiP reporter system for simultaneous identification of ER stress and antibody production in Chinese hamster ovary cells. *Metab Eng.* (2022)
- Kim HM et al. Natural Thiols, but Not Thioethers, Attenuate Patulin-Induced Endoplasmic Reticulum Stress in HepG2 Cells. *Toxins (Basel).* (2021)
- Nam MH et al. KDS2010, a newly developed reversible MAO-B inhibitor, as an effective therapeutic candidate for Parkinson's disease. *Neurotherapeutics.* (2021)
- Jung et al. Successful Correction of ALD Patient-derived iPSCs Using CRISPR/Cas9. *BioRxiv preprint.* (2020)
- [View More ...](#)

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.